Appropriate use of beta blockers in cirrhosis

Ranjan Mascarenhas; Atif Zaman

doi:10.1007/s11901-015-0278-2

Appropriate use of beta blockers in cirrhosis

Ranjan Mascarenhas
, Atif Zaman

Gastroenterology and Hepatology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Cirrhosis of the liver from various etiologies is a leading cause of morbidity and mortality in developing countries and industrialized nations alike. Beta blockers have been used for primary and secondary prophylaxis to prevent the initial episode of bleeding as well as rebleeding from gastroesophageal varices for several decades. However, the side effects of nonselective beta blockers preclude their use in all patients with cirrhosis. Recent evidence suggests that the use of beta blockers in patients with decompensated cirrhosis and refractory ascites may be contraindicated. The purpose of this review is to describe the appropriate use of beta blockers in cirrhosis taking into account emerging data.

Original language	English (US)
Pages (from-to)	243-249
Number of pages	7
Journal	Current Hepatitis Reports
Volume	14
Issue number	3
DOIs	https://doi.org/10.1007/s11901-015-0278-2
State	Published - Jul 15 2015

Funding

PLP erklärt keine Interessenskonflikte. Er hat Forschungsförderung vom BMBF, der VW Stiftung, TiLak und der Baden-Würt-temberg Stiftung erhalten. Er war als Prüf-arzt an einer klinischen Studie von Lund-beck beteiligt. Er erhält keine Honorare der pharmazeutischen Industrie, kein Besitz von Aktien, kein speaker´s bureau oder advisory board. JMF hatte in den letzten 5 Jahren Forschungsförderung von: EU, DFG, BMG, BMBF, BMFSFJ, Ländersozial-ministerien, Bundeswehr, Landesstiftung BaWü, Päpstliche Universität Gregoriana, Caritas, CJD; Reisebeihilfen, Vortragsho-norare, Veranstaltungs-und Ausbildungs-Sponsoring von: DFG, AACAP, NIMH/ NIH, EU, Goethe Institut, Pro Helvetia, Adenauer-, Böll-und Ebert-Stiftung, Shire, Fachverbände und Universitäten sowie Ministerien. Keine industriegesponserten Vortragsreihen, kein „speakers bureau“; Klinische Prüfungen und Beratertätigkeit für Servier, BMBF, Lundbeck; Mindestens jährliche Erklärung zu conflicts of interest gegenüber der DGKJP und AACAP wegen Komissionsmitgliedschaft; Kein Aktienbe-sitz, keine Beteiligungen an Pharmafirmen, bis Juni 2016 Mehrheitseigner 3Li. AI und MHL erklären keine Interessenkonflikte.

Keywords

Beta blocker
Cirrhosis
Portal hypertension
Refractory ascites
Varices

ASJC Scopus subject areas

Hepatology
Virology

Access to Document

10.1007/s11901-015-0278-2

Cite this

@article{aebba8df176d49edac132917c3726b87,

title = "Appropriate use of beta blockers in cirrhosis",

abstract = "Cirrhosis of the liver from various etiologies is a leading cause of morbidity and mortality in developing countries and industrialized nations alike. Beta blockers have been used for primary and secondary prophylaxis to prevent the initial episode of bleeding as well as rebleeding from gastroesophageal varices for several decades. However, the side effects of nonselective beta blockers preclude their use in all patients with cirrhosis. Recent evidence suggests that the use of beta blockers in patients with decompensated cirrhosis and refractory ascites may be contraindicated. The purpose of this review is to describe the appropriate use of beta blockers in cirrhosis taking into account emerging data.",

keywords = "Beta blocker, Cirrhosis, Portal hypertension, Refractory ascites, Varices",

author = "Ranjan Mascarenhas and Atif Zaman",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media New York 2015.",

year = "2015",

month = jul,

day = "15",

doi = "10.1007/s11901-015-0278-2",

language = "English (US)",

volume = "14",

pages = "243--249",

journal = "Current Hepatitis Reports",

issn = "1540-3416",

publisher = "Current Medicine Group LLC 1",

number = "3",

}

TY - JOUR

T1 - Appropriate use of beta blockers in cirrhosis

AU - Mascarenhas, Ranjan

AU - Zaman, Atif

N1 - Publisher Copyright: © Springer Science+Business Media New York 2015.

PY - 2015/7/15

Y1 - 2015/7/15

N2 - Cirrhosis of the liver from various etiologies is a leading cause of morbidity and mortality in developing countries and industrialized nations alike. Beta blockers have been used for primary and secondary prophylaxis to prevent the initial episode of bleeding as well as rebleeding from gastroesophageal varices for several decades. However, the side effects of nonselective beta blockers preclude their use in all patients with cirrhosis. Recent evidence suggests that the use of beta blockers in patients with decompensated cirrhosis and refractory ascites may be contraindicated. The purpose of this review is to describe the appropriate use of beta blockers in cirrhosis taking into account emerging data.

AB - Cirrhosis of the liver from various etiologies is a leading cause of morbidity and mortality in developing countries and industrialized nations alike. Beta blockers have been used for primary and secondary prophylaxis to prevent the initial episode of bleeding as well as rebleeding from gastroesophageal varices for several decades. However, the side effects of nonselective beta blockers preclude their use in all patients with cirrhosis. Recent evidence suggests that the use of beta blockers in patients with decompensated cirrhosis and refractory ascites may be contraindicated. The purpose of this review is to describe the appropriate use of beta blockers in cirrhosis taking into account emerging data.

KW - Beta blocker

KW - Cirrhosis

KW - Portal hypertension

KW - Refractory ascites

KW - Varices

UR - https://www.scopus.com/pages/publications/84942305090

UR - https://www.scopus.com/pages/publications/84942305090#tab=citedBy

U2 - 10.1007/s11901-015-0278-2

DO - 10.1007/s11901-015-0278-2

M3 - Article

AN - SCOPUS:84942305090

SN - 1540-3416

VL - 14

SP - 243

EP - 249

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

IS - 3

ER -

Appropriate use of beta blockers in cirrhosis

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this